Congenital melanocytic nevi: Where are we now? : Part II. Treatment options and approach to treatment - 14/09/12

Doi : 10.1016/j.jaad.2012.06.022

Omar A. Ibrahimi, MD, PhD ^a,^b, Ali Alikhan, MD ^c, Daniel B. Eisen, MD ^d,^⁎
^a Department of Dermatology, University of Connecticut Health Center, Farmington, Connecticut
^b Wellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
^c Department of Dermatology, Mayo Clinic, Rochester, Minnesota
^d Department of Dermatology, University of California Davis Medical Center, Sacramento, California

Reprint requests: Daniel B. Eisen, MD, University of California, Davis, School of Medicine, Department of Dermatology, 3301 C St, Ste 1400, Sacramento, CA 95816.

Abstract

Treatment of congenital melanocytic nevi (CMN) is generally undertaken for 2 reasons: (1) to reduce the chances of cutaneous malignant melanoma and (2) for cosmetic reasons. Over the past century, a large number of treatments for CMN have been described in the literature. These include excision, dermabrasion, curettage, chemical peels, radiation therapy, cryotherapy, electrosurgery, and lasers. Only low-level evidence supporting these approaches is available, and large randomized controlled trials have not been published. This article explores therapeutic controversies and makes recommendations based on the best available evidence.

Le texte complet de cet article est disponible en PDF.

Abbreviations used : CMN, Er:YAG, GCMN, MM, Nd:YAG, NMRL, PAS, QSRL